Components of National Drug Policya	Angola	Botswana	Dem. Rep. of the Congo	Lesotho	Malawi	Mozam- bique	Namibia	South Africa	Swaziland	Tanzania	Zambia	Zimbabwe
Essential medicines list	0	1	1	1	1	1	1	1	1	1	1	1
Price regulation	1	0	1	0	0	1	0	1	0	0	0	0
NHI or SHI	0	0	0	0	1	1	0	0	0	1	0	1
Free HIV/AIDS medicines programb	1	1	1	1	1	1	1	1	1	1	1	1
Procurement Strategy	0	0	1	1	1	1	1	1	0	1	1	1
R&D capacity	0	0	1	0	0	0	0	1	0	0	1	0
Year of survey	2009	2009	2009	2009	2009	2010	2009	2009	2009	2009	2009	2009
PEPFAR focus country? (as of 2008)	0	1	0	0	0	1	1	1	0	1	1	0
CHAI Program Country? (as of 2014)	0	0	0	1	1	1	1	1	1	1	1	1

Appendix 2 shows our assessment of countries’ national drug policies based on responses given in their Country Data Profile and our methodology detailed in Appendix 1. For our paper, each country was assessed on six components of national drug policies, as highlighted by the WHO guidelines How to Develop and Implement a National Drug Policy, based on survey responses in their Country Data Profile.¹¹ Five of these policy components—essential medicines list, price regulation, NHI or SHI, procurement strategy and R&D capacity—were included in our paper’s regression models (regression results shown in Tables 1 and 2) based on their theoretical importance to ARV price. However, whether a country had a free HIV/AIDS medicines program was not included in our regression model because there was no variation in this policy among SADC countries (e.g. all 12 SADC countries in the regression model had free programs for HIV/AIDS medicines).

^aKey: 1 = policy component met, 0 = policy component not met.

^bNot included in regression models.